5248242025-07-012025-09-305248242025-09-305248242025-03-315248242025-04-012025-09-305248242025-07-012025-09-30in-capmkt:OtherExpenses1Member5248242025-04-012025-09-30in-capmkt:OtherExpenses1Member5248242025-07-012025-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524824BALPHARMANOTLISTEDINE083D01012BAL PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312025-11-122025-11-04INRLakhsQuarterlySecond quarterSingle segmentPHARMACEUTICLES2025-11-1216:30:002025-11-1217:30:00trueCash Flow IndirectDeclaration of unmodified opinion2025-07-012025-09-30UnauditedConsolidated7402490001115900075140800040291700017786000-21350000162714000385800002271000012087800074423500071730000717300000007173000000071730000717300070950007700000159209000100.450.45000.450.451.The above unaudited financial results has been reviewed by the audit committee and approved by the Board of Directors at their respective meetings held on 12.11.2025. <BR> <BR> 2. The consolidated financial results have been prepared with the Companies / Indian accounting standard rules , 2015, prescribed under Section 133 of Companies Act,2013, read wwith relevant rules issued there under and the recognised accounting practises and policies to the extent applicable. The financial results relates to Bal Pharma Ltd to its subsidiaries ( Togather called as group ) , JV's, associates and are prepared applying IND AS 110- Consolidated financials and IND AS 28 - Investment in associates and joint ventures. <BR> 3. The figures for the year ended 31st March 2025 and 2024 are the balancing figures between the audited figures in respect of full financial year and unaudited published year to date figures upto the third quarter of the relevant financial year whech were subjected to limited review by statutory auditors. <BR> 4. The Company has only one reportable segment i.e Pharmaceuticles. <BR> 5. Previous period figures have been regrouped/rearranged whereever required to confirm to the period presentation. <BR> 2025-04-012025-09-30UnauditedConsolidated139895800018381000141733900076320200057633000-8605600031075100079114000479140002355230001408081000925800009258000000092580000000925800009258000910200015700000159209000100.570.57000.570.57Other Expenses120878000Other Expenses2355230007619730003008300038269000124655000004818400048184000409800036349000104361100011269160004024000908235000158070007142700011909000153010001026703000318000296158000245009500000349370600015920900062405200078326100043000783304000313668000000549530003686210005281500000042143600012351230000842035000842035000137746000221490400062422000116400000022889660000027104020003493706000-5007000-2850000-363100079114000-2927000047914000000000-96695000198320001149000-1526000-301210002517600068231000-3357000-3655000000006574100030205000394630000000039463000-4191900000342350000005007000-4660000045126000000000-79114000000000000000-205867000-170800000008010000043530001065400000000-8810000-1752140000-1752140000-175214000UnauditedtrueSSJNB & COtrue2026-03-31